Arce Renteria M, Mobley TM, Evangelista ND, Medina LD, Deters KD, Fox-Fuller JT, Avila-Rieger, Bettcher BM. Representativeness of Samples Enrolled in Alzheimer’s Disease Centers. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2023 Jun 5; doi: 10.1002/dad2.12450.

Robinson T, Klinger H, Buckley R, Deters KD, Quiroz Y, Rentz D, Rabin JS, Sperling R, Amariglio R. Evaluation of ethnoracial differences in self- and study partner-reported subjective cognitive decline in the A4 study screen data. Alzheimer’s & Dementia. 2023 May 23; doi: 10.1002/alz.13138.

Wang X, Broce-Diaz I, Qiu Y, Deters KD, Fan CC, Dale AM, Edland ST, Banks SJ, and for the Alzheimer’s Disease Neuroimaging Initiative. A simple genetic stratification method for lower cost, more expedient clinical trials in early Alzheimer’s disease: A preliminary study of Tau PET and cognitive outcomes. Alzheimer’s & Dementia. 2023 Jan 6; doi: 10.1002/alz.12952.

Wang X, Broce, I, Deters KD, Fan CC, Banks SJ. Identification of sex-specific genetic variants associated with tau PET. Neurol Genet. 2022 Dec 8; doi: 10.1212/NXG.0000000000200043.

Deters KD, Napolioni V, Sperling RA, Greicius MD, Mayeux R, Hohman T, and Mormino EC. Amyloid PET imaging in self-identified non-Hispanic Blacks from the Anti-Amyloid in Asymptomatic Alzheimer’s Disease (A4) Study. Neurology. 2021. DOI: 10.1212/WNL.0000000000011599. Highlighted with an editorial.

Manly JC, Bykovskyi AG, Deters KD. Inclusion of underrepresented groups in preclinical Alzheimer’s disease trials: Opportunities abound. JAMA Netw Open. 2021 Jul 1; doi:10.1001/jamanetworkopen.2021.14606

Deters KD, Mormino EC, Yu L, Lutz M, Bennett DA, and Barnes LL. TOMM40-APOE haplotypes are associated with cognitive decline in non-demented Blacks. Alzheimer’s & Dementia. 2021.

Winer JR, Deters KD, Kennedy G, Jin M, Goldstein-Piekarski A, Poston KL, Mormino EC. Short and long sleep duration are associated with distinct aging pathways. JAMA Neurol. 2021 Aug 30; doi: 10.1001/jamaneurol.2021.2876.

Belloy ME, Eger SJ, Leguen Y, Napolioni V, Deters KD, Yang HS, Scelsi MA, Porter T, James SN, Wong A, Schott JM, Sperling RA, Laws SM, Mormino EC, He Z, Han SS, Altmann A, and Greicius MD. KL-VS Heterozygosity Reduces Brain Amyloid in Pre-Symptomatic APOE4 Carriers. Neurobiology of Aging. 2021.

Avila JF, Rentería MA, Jones RN, Vonk JM, Turney I, Sol K, Nika Seblova N, Arias F, Hill-Jarrett T, Levy SA, Meyer O, Racine AM, Tom SE, Melrose RJ, Deters K, Medina LD, Carrión CI, Díaz-Santos M, Byrd DR, Chesebro A, Colon J, Igwe KC, Maas B, Brickman AM, Schupf N, Mayeux R, and Jennifer Manly J. Education Differentially Contributes to Cognitive Reserve Across Racial/Ethnic Groups. Alzheimer’s & Dementia. 2020.

Deters KD, Risacher SL, Kim S, Nho K, West JD, Blennow K, Zetterberg H, Shaw L, Trojanowski J, Weiner MW, and Saykin AJ for the Alzheimer Disease Neuroimaging Initiative. Plasma tau association with brain atrophy in mild cognitive impairment and Alzheimer’s disease. Journal of Alzheimer’s Disease. 2017; 58(4):1245-1254.

Deters KD, Nho K, Risacher SL, Kim S, Ramanan V, Crane PK, Apostolova LG, Saykin AJ, and the Alzheimer Disease Neuroimaging Initiative. Genome-wide association study of language performance in Alzheimer’s disease. Brain & Language. 2017; 172:22-29.

 Deters KD*, Risacher SL*, Yoder KK, Oblak AL, Unverzagt FW, Murrell JR, Epperson F, Tallman EF, Quaid KA, Farlow MR, Saykin AJ, and Ghetti B. [11-C]PiB PET in Gerstmann–Sträussler–Scheinker Disease. American Journal of Nuclear Medicine and Molecular Imaging. 2016; 6(1):84-93. *Dual first authors

Deters KD, Risacher SL, Farlow MR, Unverzagt FW, Kareken DA, Hutchins GD, Yoder KK, Murrell JR, Spina S, Epperson F, Gao S, Saykin AJ, and Ghetti B. Cerebral hypometabolism and grey matter density in MAPT intron 10 + 3 MAPT mutation carriers. American Journal of Neurodegenerative Disease. 2014; 3(3): 103-114.